RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview

Nuvation Bio Inc. (NYSE:NUVB) is one of the best small cap stocks to buy with the highest upside potential. RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note previewing fiscal Q2 earnings in Biotech, with the firm telling investors in the research note that the biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P.

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

This was driven by strong data expanding innovative spaces and perceptions around improving FDA flexibility/stability. The firm further added that with outlooks more concretely definable than other high-volatility spaces, it believes capital could continue to flow in. It also stated that fiscal Q2 earnings are shaping up to be seasonally strong, and with multiple opportunities for beats and the M&A resurgence likely to continue, there is little that would materially derail things.

Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops novel therapeutic and differentiated candidates to tackle the gaps in oncology. The company’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1